NL-OMON45514尚未招募不适用
NVALT2017 / Translational research for immune modulating and targeted therapy in non-small cell lung cancer, an exploratory NVALT study - Translational research for immune modulating and targeted therapy in NSCLC
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Eligible for immunotherapy or targeted treatment.
- •2. Written informed consent for registry of patient data and extra blood and tumor biopsy.
- •3. Age * 18 years.
排除标准
- •1. Without written informed consent patient will be adopted anonymously in the registry and will not take part of the study.
- •2. Patients with written informed consent for registry of patient data but no consent for extra blood and tumor biopsy will be excluded from the study.
研究者
相似试验
尚未招募
不适用
Translational research for immune modulating and targeted therapy in advanced or metastatic non-small cell lung cancer, an exploratory NVALT studyon-small cell lung cancerNiet-kleincellig longkankerNL-OMON23268VALT300
招募中
不适用
PROFIT: PRospective studie OF Immune Tolerance induction (ITI)bleeding disordercoagulation disorder1006447710005330NL-OMON48806niversitair Medisch Centrum Utrecht18
Unknown
不适用
Feasibility 'innate' allogeneic stem cells transplantioHematological malignancies (hematologische maligniteiten)Allogeneic stem cells transplantation (allogene stamcel transplantatie)Innate immune system (aangeboren immuunsysteem)NL-OMON25484MC UtrechtHeidelberglaan 1003584 CX Utrecht35
招募中
2 期
Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB (T3N2 only) non-squamous Non-Small Cell Lung Cancer (NSCLC) to neoadjuvant ATEZOLIZUMAB plus Carboplatin/Nab PaclitaxelLung cancer2024-516590-75-00Universitaetsklinikum Heidelberg AöR, Universitaetsklinikum Heidelberg AöR20
尚未招募
Unknown
To find Natural killers cells as a treatment option for Triple negative breast cancer.CTRI/2023/10/058292Tata Memorial Center